FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161732103> ?p ?o ?g. }

• W2161732103 endingPage "541" @default.
• W2161732103 startingPage "534" @default.
• W2161732103 abstract "OBJECTIVE Dopamine agonists have a well established place in the treatment of hyperprolactinaemic disorders but their use is associated with a high incidence of adverse effects. We have investigated the biochemical efficacy and side-effect profile of a range of doses of the novel, long-acting dopamine agonist, cabergoline, in suppressing prolactin (PRL) in hyperprolactinaemic women. DESIGN Multicentre, prospective, randomized, placebo controlled and double blind. PATIENTS One hundred and eighty-eight women with hyperprolactinaemia secondary to microprolactinoma (n= 113), idiopathic disease (n= 67), empty sella syndrome (n= 7) or following failed surgery for a macroprolactinoma (n= 1). MEASUREMENTS Weekly assessment of adverse symptoms, blood pressure and pulse, serum PRL, blood count, liver and renal function. RESULTS Patients received either placebo (n= 20) or cabergoline 0.125 (n= 43), 0.5 (n= 42), 0 75 (n= 42) or 10 mg (n= 41) twice weekly for 4 weeks. The five treatment groups were comparable in age (mean 31.8, range 16– 46 years), diagnosis, previous therapy, and pretreatment serum PRL. PRL was suppressed to below half the pretreatment level in 5,60,90,95 and 98% and normalized in 0, 30, 74, 74 and 95% of patients taking placebo or cabergoline 0.125, 0.5, 0.75 or 1.0 mg twice weekly respectively (Armitage's test, χ2= 39.3, P < 0.01). Cabergoline therapy (all doses) restored menses in 82% of the amenorrhoeic women not previously treated with dopamine agonists. Adverse events were recorded in 45% of patients in the placebo group and in 44, 50, 50 and 58% of those taking 0.125, 0.5, 0.75 and 1.0 mg cabergoline twice weekly (Armitage's test, P < 0.05). Over 95% of reported symptoms were relatively trivial, most frequently transient nausea, headache, dizziness, fatigue and constipation. More severe adverse events, interfering significantly with the patients’ lifestyle, occurred in 13 (7.7%) patients taking cabergoline; treatment withdrawal was necessary in only one case. No adverse effects were detected on blood pressure or haematological or biochemical parameters. CONCLUSIONS We have shown a linear dose-response relationship for cabergoline in the treatment of hyperprolactinaemia in the range 0.125– 1.0 mg twice weekly, with normalization of PRL in up to 95% of cases and acceptable tolerability throughout the dose range." @default.
• W2161732103 created "2016-06-24" @default.
• W2161732103 creator A5010617126 @default.
• W2161732103 creator A5015696343 @default.
• W2161732103 creator A5043502287 @default.
• W2161732103 creator A5046234432 @default.
• W2161732103 creator A5062388816 @default.
• W2161732103 creator A5068211240 @default.
• W2161732103 creator A5068544225 @default.
• W2161732103 creator A5070463166 @default.
• W2161732103 creator A5083634538 @default.
• W2161732103 creator A5089683087 @default.
• W2161732103 date "1992-12-01" @default.
• W2161732103 modified "2023-10-16" @default.
• W2161732103 title "Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study" @default.
• W2161732103 cites W1987413422 @default.
• W2161732103 cites W2016210258 @default.
• W2161732103 cites W2038981184 @default.
• W2161732103 cites W2071290982 @default.
• W2161732103 cites W2074337014 @default.
• W2161732103 cites W2075593856 @default.
• W2161732103 cites W2085999153 @default.
• W2161732103 cites W2095447116 @default.
• W2161732103 cites W2169632325 @default.
• W2161732103 cites W2409620426 @default.
• W2161732103 cites W4240633689 @default.
• W2161732103 cites W2003279575 @default.
• W2161732103 doi "https://doi.org/10.1111/j.1365-2265.1992.tb01485.x" @default.
• W2161732103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1286524" @default.
• W2161732103 hasPublicationYear "1992" @default.
• W2161732103 type Work @default.
• W2161732103 sameAs 2161732103 @default.
• W2161732103 citedByCount "56" @default.
• W2161732103 countsByYear W21617321032012 @default.
• W2161732103 countsByYear W21617321032013 @default.
• W2161732103 countsByYear W21617321032014 @default.
• W2161732103 countsByYear W21617321032015 @default.
• W2161732103 countsByYear W21617321032016 @default.
• W2161732103 countsByYear W21617321032017 @default.
• W2161732103 countsByYear W21617321032018 @default.
• W2161732103 countsByYear W21617321032019 @default.
• W2161732103 countsByYear W21617321032021 @default.
• W2161732103 countsByYear W21617321032022 @default.
• W2161732103 countsByYear W21617321032023 @default.
• W2161732103 crossrefType "journal-article" @default.
• W2161732103 hasAuthorship W2161732103A5010617126 @default.
• W2161732103 hasAuthorship W2161732103A5015696343 @default.
• W2161732103 hasAuthorship W2161732103A5043502287 @default.
• W2161732103 hasAuthorship W2161732103A5046234432 @default.
• W2161732103 hasAuthorship W2161732103A5062388816 @default.
• W2161732103 hasAuthorship W2161732103A5068211240 @default.
• W2161732103 hasAuthorship W2161732103A5068544225 @default.
• W2161732103 hasAuthorship W2161732103A5070463166 @default.
• W2161732103 hasAuthorship W2161732103A5083634538 @default.
• W2161732103 hasAuthorship W2161732103A5089683087 @default.
• W2161732103 hasConcept C126322002 @default.
• W2161732103 hasConcept C126894567 @default.
• W2161732103 hasConcept C134018914 @default.
• W2161732103 hasConcept C137183658 @default.
• W2161732103 hasConcept C142724271 @default.
• W2161732103 hasConcept C197934379 @default.
• W2161732103 hasConcept C204787440 @default.
• W2161732103 hasConcept C27081682 @default.
• W2161732103 hasConcept C2778258207 @default.
• W2161732103 hasConcept C2778375690 @default.
• W2161732103 hasConcept C2779064019 @default.
• W2161732103 hasConcept C2779832395 @default.
• W2161732103 hasConcept C2781401123 @default.
• W2161732103 hasConcept C513476851 @default.
• W2161732103 hasConcept C71315377 @default.
• W2161732103 hasConcept C71924100 @default.
• W2161732103 hasConcept C90924648 @default.
• W2161732103 hasConceptScore W2161732103C126322002 @default.
• W2161732103 hasConceptScore W2161732103C126894567 @default.
• W2161732103 hasConceptScore W2161732103C134018914 @default.
• W2161732103 hasConceptScore W2161732103C137183658 @default.
• W2161732103 hasConceptScore W2161732103C142724271 @default.
• W2161732103 hasConceptScore W2161732103C197934379 @default.
• W2161732103 hasConceptScore W2161732103C204787440 @default.
• W2161732103 hasConceptScore W2161732103C27081682 @default.
• W2161732103 hasConceptScore W2161732103C2778258207 @default.
• W2161732103 hasConceptScore W2161732103C2778375690 @default.
• W2161732103 hasConceptScore W2161732103C2779064019 @default.
• W2161732103 hasConceptScore W2161732103C2779832395 @default.
• W2161732103 hasConceptScore W2161732103C2781401123 @default.
• W2161732103 hasConceptScore W2161732103C513476851 @default.
• W2161732103 hasConceptScore W2161732103C71315377 @default.
• W2161732103 hasConceptScore W2161732103C71924100 @default.
• W2161732103 hasConceptScore W2161732103C90924648 @default.
• W2161732103 hasIssue "6" @default.
• W2161732103 hasLocation W21617321031 @default.
• W2161732103 hasLocation W21617321032 @default.
• W2161732103 hasOpenAccess W2161732103 @default.
• W2161732103 hasPrimaryLocation W21617321031 @default.
• W2161732103 hasRelatedWork W2021147026 @default.
• W2161732103 hasRelatedWork W2049103486 @default.
• W2161732103 hasRelatedWork W2763326319 @default.
• W2161732103 hasRelatedWork W2897296051 @default.

• next